Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma

  1. San-Miguel, J.
  2. Bladé, J.
  3. Shpilberg, O.
  4. Grosicki, S.
  5. Maloisel, F.
  6. Min, C.-K.
  7. Zarzuela, M.P.
  8. Robak, T.
  9. Prasad, S.V.S.S.
  10. Goh, Y.T.
  11. Laubach, J.
  12. Spencer, A.
  13. Mateos, M.-V.
  14. Palumbo, A.
  15. Puchalski, T.
  16. Reddy, M.
  17. Uhlar, C.
  18. Qin, X.
  19. Van De Velde, H.
  20. Xie, H.
  21. Orlowski, R.Z.
Journal:
Blood

ISSN: 1528-0020 0006-4971

Year of publication: 2014

Volume: 123

Issue: 26

Pages: 4136-4142

Type: Article

DOI: 10.1182/BLOOD-2013-12-546374 GOOGLE SCHOLAR

Sustainable development goals